LAST WEEK, Glenmark announced that its subsidiary, Ichnos Sciences, had entered a licensing agreement for the OX-40 antagonist, Telazorlimab (ISB 830), with Astria Therapeutics. Astria will take over the product’s development and hold global rights, aiming to create a next-generation Telazorlimab with 10x higher potency. In return, Ichnos expects to receive $320 million in upfront […]